By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Glaxo Group Ltd. et al. v. Lupin Ltd. et al.
1:08-cv-00551; filed August 29, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 5,859,021 ("Antiviral Combinations," issued January 12, 1999) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Glaxo's Combivir® (lamivudine and zidovudine, used in the treatment of HIV-1 infection). View the complaint here.
Teva Pharmaceutical Industries Ltd. et al. v. Glenmark Generics Inc., USA et al.
3:08-cv-04355; filed August 29, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,699,997 ("Carvedilol," issued March 2, 2004) and 7,126,008 (same title, issued October 24, 2006) based on Glenmark's sale and/or manufacture of a generic version of GSK's Coreg® (carvedilol, used to treat congestive heart failure). View the complaint here.
Pfizer Inc. et al. v. Impax Laboratories, Inc.
2:08-cv-04356; filed August 29, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,382,600 ("3,3-Diphenylpropylamines and Pharmaceutical Compositions Thereof, issued January 17, 1995), 6,630,162 ("Pharmaceutical Formulation and Its Use," issued October 7, 2003), and 6,770,295 ("Therapeutic Formulation for Administering Tolterodine with Controlled Release," issued August 3, 2004) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Pfizer's Detrol LA® (extended release tolterodine tartrate, used to treat overactive bladder). View the complaint here.
Teva Pharmaceuticals USA, Inc. et al. v. Sandoz, Inc. et al.
1:08-cv-07611; filed August 28, 2008 in the Southern District of New York
Infringement of U.S. Patent Nos. 7,199,098 ("Copolymer-I Improvements in Compositions of Copolymers," issued April 3, 2007), 6,939,539 (same title, issued September 6, 2005), 6,054,430 (same title, issued April 25, 2000), and 6,620,847 (same title, issued September 16, 2003) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Teva's Copaxone® (glatiramer acetate injection, used for the reduction of frequency of relapses in patients with relapsing-remitting multiple sclerosis). View the complaint here.
Comments